SCHEMBL1809334

SCHEMBL1809334

ON=C1CCCc2cc(Br)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 1/20 0.50
SRD5A1 P18405 1/20 0.44
SRD5A2 P31213 1/20 0.44
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PPARG P37231 1/20 0.42
NCOA2 Q15596 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PARP10 Q53GL7 1/20 0.41
PARP11 Q9NR21 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.37
CYP19A1 P11511 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11971363 1.00 HPGD (0.53) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL16621035 1.00 HPGD (0.53) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL2306872 0.89 HTT (0.62) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL2306868 0.89 HTT (0.62) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL11898554 0.89 HTT (0.62) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL10144900 0.87 METAP1 (0.45) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL571311 0.87 METAP1 (0.45) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL571312 0.87 METAP1 (0.45) HPGDL3MBTL1HTTSRD5A1SRD5A2
SCHEMBL23950429 0.86 L3MBTL1 (0.53) HPGDL3MBTL1HTTMAPTMEN1
SCHEMBL15956234 0.86 L3MBTL1 (0.53) HPGDL3MBTL1HTTMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof BEIGENE SWITZERLAND GMBH (CH) 2025-05-15 US disclosed
US-12185626-B2 Chemical compounds, optoelectronic elements comprising at least one new chemical compound, and use of new chemical compounds in an optoelectronic element HELIATEK GMBH (DE) 2024-12-31 US disclosed
EP-3890041-B1 NEW CHEMICAL COMPOUNDS, OPTOELECTRONIC ELEMENTS COMPRISING AT LEAST ONE NEW CHEMICAL COMPOUND, AND USE OF NEW CHEMICAL COMPOUNDS IN AN OPTOELECTRONIC ELEMENT HELIATEK GMBH (DE) 2024-12-04 EP disclosed
EP-4448513-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BeiGene Switzerland GmbH (CH) 2024-10-23 EP disclosed
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2024-08-01 US disclosed
CN-118401514-A 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof 百济神州有限公司 2024-07-26 CN disclosed
CN-117946138-A And ring nitrogen-containing compound, intermediate thereof, preparation method and application 杭州圣域生物医药科技有限公司 2024-04-30 CN disclosed
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-10-17 US disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed
US-20230165146-A1 CHEMICAL COMPOUNDS, OPTOELECTRONIC ELEMENTS COMPRISING AT LEAST ONE NEW CHEMICAL COMPOUND, AND USE OF NEW CHEMICAL COMPOUNDS IN AN OPTOELECTRONIC ELEMENT HELIATEK GMBH (DE) 2023-05-25 US disclosed
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2016-06-09 US disclosed
US-20160157491-A1 Pesticide Compounds BASF SE (DE) 2016-06-09 US disclosed
EP-3022185-A1 PESTICIDE COMPOUNDS BASF SE (DE) 2016-05-25 EP disclosed
US-9216972-B2 Tricyclic heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-22 US disclosed
WO-2015049535-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-04-09 WO disclosed
WO-2015007682-A1 PESTICIDE COMPOUNDS BASF SE (DE) 2015-01-22 WO disclosed
EP-2592071-A1 Tricyclic heterocyclic compounds Bristol-Myers Squibb Company (US) 2013-05-15 EP disclosed
EP-2493866-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2012-09-05 EP disclosed
US-20120214767-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2012-08-23 US disclosed
WO-2011059784-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157491-A1 Pesticide Compounds C1R, C1S, CBR3 HPGD 4430/4885L3MBTL1 705/4885HTT 1002/4885
US-20120214767-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS S1PR1, S1PR3, TBXA2R HPGD 957/4885L3MBTL1 4429/4885HTT 3837/4885
US-20230165146-A1 CHEMICAL COMPOUNDS, OPTOELECTRONIC ELEMENTS COMPRISING AT LEAST ONE NEW CHEMICAL COMPOUND, AND USE OF NEW CHEMICAL COMPOUNDS IN AN OPTOELECTRONIC ELEMENT ETV6, ALK, CHRM3 HPGD 4655/4885L3MBTL1 1636/4885HTT 2009/4885
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 HPGD 197/4885L3MBTL1 1986/4885HTT 528/4885
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 HPGD 1580/4885L3MBTL1 3899/4885HTT 89/4885
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 HSF1, HSP90AB1, HSPB1 HPGD 197/4885L3MBTL1 1986/4885HTT 528/4885
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof STING1, IRF3, MAVS HPGD 1514/4885L3MBTL1 2338/4885HTT 4338/4885
US-12185626-B2 Chemical compounds, optoelectronic elements comprising at least one new chemical compound, and use of new chemical compounds in an optoelectronic element ETV6, ALK, CHRM3 HPGD 4655/4885L3MBTL1 1636/4885HTT 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.